NCT05156814Unknown4 期
A Prospective, Multicenter, Randomized, Open-label, Comparative Study in Three Parallel Groups to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone (Femoston® 1 or Femoston® 2, Coated Tablets) and the Combination Therapy of Dydrogesterone (Duphaston®, Coated Tablets) Plus Estradiol (Divigel, Gel for Topical Application, 0.1%) and Monotherapy With Cimicifuga Racemosa Rhizomatum Extract (Klimadynon®) in Perimenopausal Women
Scientific Research Institute of Public Health, Russian Federation1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2021年11月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Changes in the average number of "hot flashes" per day* as percentages according to data from the patient diary after 84 days (3 cycles) since the initiation of treatment compared to baseline (Visit 0).
研究概览
简要总结
To obtain new data allowing personalizing continuous hormonal therapy in perimenopausal women in Russia, the following clinical study is going to be conducted in the Russian Federation:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Caucasian women in perimenopause (STRAW -1/ +1a) with an intact uterus.
- •Age from 40 to 55 years old as of the time of screening.
- •Absence of natural menstruations within 4 months, but not longer than for 12 months.
- •50 or more episodes of "hot flashes" in the last 7 days according to the patient diary (at the screening).
- •Patients scoring more than 12 points on the Greene Scale.
- •Follicle-Stimulating Hormone (FSH) levels more than 25 IU/L, estradiol levels less than 190 pmol/L.
- •Consent to the use of barrier methods of contraception.
- •Body mass index <30 kg / m
- •Signed Informed Consent Form.
- •Mammography performed within 6 months prior to inclusion in the study.
- •Absence of clinically significant deviations according to the results of medical examination: physical examination (including assessment of the state of the mammary glands), measurement of indicators of vital body functions (blood pressure, heart rate, respiratory rate and body temperature) and gynecological examination.
- •The patient's consent to perform all research procedures and adhere to all restrictions provided for by the research protocol.
排除标准
- •Administration of drugs from the prohibited therapy list.
- •Known hypersensitivity to estradiol, dydrogesterone, to the active component of the drug Klimadynon® (dry extract of rhizomes of cimicifuga racemose) or to any of the excipients of the study drugs.
- •Pregnancy and breastfeeding.
- •Abnormal uterine bleeding from the vagina of unclear etiology within 12 months before the screening stage.
- •Breast cancer (diagnosed, suspected, or past).
- •Estrogen-dependent malignancies of the sex organs, including endometrial cancer (diagnosed, suspected, or past).
- •Known or suspected progestogen-dependent neoplasms (e.g. meningioma).
- •Untreated endometrial hyperplasia.
- •Venous and arterial thrombosis/thromboembolism, currently or in history (including deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic or hemorrhagic stroke; angina pectoris, transient ischemic attack).
- •Diagnosed hereditary or acquired predisposition to arterial or venous thrombosis/thromboembolism (eg, hyperhomocysteinemia, deficiency of protein C, protein S or antithrombin III, the presence of antiphospholipid antibodies).
- •Acute or chronic liver disease in history (in case of deviation from a norm of liver function indicators); benign and malignant liver tumors (including hemangioma, adenoma, liver cancer) or an increase in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) activity detected during screening by more than 1.5 times relative to the upper limit of normal.
- •Brain disorders and traumas.
- •Galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.
- •Cholestatic jaundice and/or severe cholestatic itching (especially during a previous pregnancy or sex hormone intake).
- •Uncontrolled hypertension.
- •Diabetes mellitus.
- •Adenomyosis grade >3 and uterine myoma (more than 3 nodes with an intermuscular or subserous arrangement with a diameter of more than 3 cm) and / or centripetal growth/submucous node location.
- •Cholelithiasis.
- •Systemic lupus erythematosus.
- •Bronchial asthma.
- •Otosclerosis.
- •Known renal or hepatic insufficiency.
- •Ovarian cysts >6 mm based on results of ultrasound scanning.
- •Endometrial thickness ≥5 mm according to transvaginal ultrasound.
- •Migraine headache or a history of severe migraine-type headaches.
- •Other medical conditions which could interfere with the study-related procedures and/or influence the efficacy of the study drug.
- •Simultaneous intake of excluded drugs.
- •Participation in any other clinical study within 3 months before screening.
- •Pathological result of smear for cytology (PAP test) and Human papillomavirus (HPV) test.
- •The use of estrogens or combination drugs for hormone replacement therapy (HRT) within 6 months before the start of the study.
- •Higher risk of thromboembolic complications due to prolonged immobilization for 2 weeks before the screening stage (for example, as a result of trauma or surgery).
- •Previous major surgical interventions (including abdominal) within 6 months before the start of the study.
- •Tumor of the pituitary gland.
- •Severe pathology of the cardiovascular system: complicated lesions of the valvular apparatus of the heart, uncontrolled drug arrhythmia, chronic heart failure I - IV functional class.
- •Sickle cell anemia.
- •Congenital hyperbilirubinemia (Gilbert, Steven-Johnson and Rotor).
- •A history of pancreatitis with severe hypertriglyceridemia.
- •Polyp in the uterine cavity.
- •Use of any drugs in the form of prolonged-release injections or implants within 3 months before the screening stage.
- •A history of any other malignant neoplasms within 5 years prior to the study, with the exception of adequately treated squamous cell skin cancer.
- •Anamnestic data on any clinically significant disease of the kidneys, lungs, gastrointestinal tract, skin and subcutaneous tissues, musculoskeletal system, blood and lymphatic system, nervous system.
- •Positive blood test for HIV, hepatitis B and C, syphilis.
- •Alcoholism, drug addiction in history.
- •Prior endometrial ablation therapy.
研究组 & 干预措施
Combination therapy with estradiol and dydrogesterone
Active Comparator
Duphaston®, 10 mg and Divigel, 0.1%
干预措施: Divigel (Drug)
Fixed-dose Combination (FDC) estradiol / dydrogesterone
Experimental
Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
干预措施: Femoston® 1, Femoston® 2 (Drug)
Combination therapy with estradiol and dydrogesterone
Active Comparator
Duphaston®, 10 mg and Divigel, 0.1%
干预措施: Duphaston (Drug)
non-hormonal therapy
Active Comparator
Cimicifuga racemosa rhizomatum extract (Klimadynon®)
干预措施: Klimadynon (Drug)
结局指标
主要结局
Changes in the average number of "hot flashes" per day* as percentages according to data from the patient diary after 84 days (3 cycles) since the initiation of treatment compared to baseline (Visit 0).
时间窗: 84 days
次要结局
- The frequency of "hot flashes" after 84 days since the initiation of treatment.(84 days)
- The average treatment satisfaction score according to the Likert Scale after 84, 168, and 364 days since the initiation of treatment.(84 days, 168 days, 364 days)
- The change in the total score on the Greene Climacteric Scale at the end of the therapy (364 days) compared to baseline.(364 days)
- Changes according to the Greene Climacteric Scale in each of the 4 subscales after 84, 168, and 364 days since the initiation of treatment compared to baseline (Visit 0).(84 days, 168 days, 364 days)
- Changes in the intensity of of menopausal symptoms calculated using the Menopause Rating Scale (MRS) after 84, 168, and 364 days since the treatment initiation compared to baseline (Visit 0).(84 days, 168 days, 364 days)
- Changes according to the "Hot Flush" Related Daily Interference Scale (HFRDIS) after 84, 168, and 364 days since the initiation of treatment compared to baseline (Visit 0).(84 days, 168 days, 364 days)
- Changes in the adipose tissue according to densitometry results after 364 days of treatment compared to baseline (Visit 0).(364 days)
- Changes in the waist circumference after 364 days of treatment compared to baseline (Visit 0).(364 days)
- Changes in the bone tissue according to densitometry results after 364 days of treatment compared to baseline (Visit 0).(364 days)
- Changes in the bone resorption marker β-Cross laps after 364 days of treatment compared to baseline (Visit 0).(364 days)
- Changes in the bone formation marker (P1NP) after 364 days of treatment compared to baseline (Visit 0).(364 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleHealthy SubjectsNCT05551897AstraZeneca14
已完成
1 期
Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the BodyVasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenNCT04845841Bayer16
终止
3 期
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantBreast CancerNCT03439046Novartis Pharmaceuticals287
已完成
1 期
A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenNCT05028608Bayer16
已完成
1 期
A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female ParticipantsVasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenNCT04903821Bayer33